
|Articles|February 1, 2005
New agents show promise in melanoma
Tampa, Fla. — Among molecularly targeted agents being developed to treat melanoma, some of the most exciting are anti-CTLA-4 antibodies now being developed by Pfizer and Medarex.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians See Intersection of Weight Loss and Facial Aging
2
The “6-7” Advances for Dermatologists to Look Forward to in 2026
3
Q&A: Saami Khalifian, MD, FAAD, on Integrating BOTOX Cosmetic into Lower Face and Neck Rejuvenation
4
Soquelitinib Phase 1 Data Show Sustained Clinical Improvement With Extended Treatment in AD
5


















